News Search Results
Sep 14, 2025, 20:00 ET Corero Network Security Bermitra dengan Nextwave Untuk Perluas Perlindungan DDoS Ke Thailand
Corero Network Security (AIM: CNS) (OTCQX: DDOSF) adalah perusahaan terdepan yang diakui dalam hal perlindungan DDoS dan piawai dalam ketersediaan layanan di waktu nyata yang dapat disesuaikan.
More news about: Corero Network Security
Sep 13, 2025, 11:50 ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
$17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class
More news about: Faruqi & Faruqi, LLP
Sep 13, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Sep 11, 2025, 12:00 ET Zhimeng Biopharma's Investigational Drug Approved to Initiate Phase 2 Epilepsy Clinical Trial in China
small-molecule drug discovery focused on the functional cure of chronic hepatitis B (CHB), as well as novel therapies for CNS disorders, including epilepsy, neuropathic pain (e.g., cancer-related pain), amyotrophic lateral sclerosis (ALS), major depressive disorder (MDD), and
More news about: Shanghai Zhimeng Biopharma, Inc.
Sep 11, 2025, 09:41 ET Gene Solutions Secures Patent(1) for Breakthrough Mitochondrial Therapy Platform Targeting Neurological Diseases
Sept. 11, 2025 /PRNewswire/ -- Gene Solutions, a leader in mitochondrial dysfunction genomics and CNS drug discovery, announces the publication of its platform technology patent. The award covers novel technologies underpinning the company's platform
More news about: Gene Solutions
Sep 11, 2025, 08:46 ET Korea University Study Reveals Hidden Complexity in Recurrent Brain Tumors
2025 /PRNewswire/ --Meningiomas are the most common primary brain tumors, accounting for nearly one-third of all central nervous system (CNS) tumors. While most are benign and manageable, 20–30% progress to high-grade forms that behave aggressively, recur frequently, and resist standard treatments.
More news about: Korea University College of Medicine
Sep 11, 2025, 08:00 ET Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy
standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the
More news about: Kazia Therapeutics Limited
Sep 11, 2025, 07:00 ET Corero Network Security Partners with Nextwave to Expand DDoS Protection into Thailand
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, announced a strategic partnership with
More news about: Corero Network Security
Sep 10, 2025, 16:45 ET Cohen & Steers Infrastructure Fund, Inc. Declares Distribution for October 2025
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Sep 10, 2025, 16:27 ET Cohen & Steers Infrastructure Fund, Inc. Announces Terms of Transferable Rights Offering
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Sep 10, 2025, 14:30 ET NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
draw into actionable, patient-specific insights, accelerating innovation for people living with AD." These results will be presented at the CNS Summit 2025 in Boston, November 2nd – 5th by David
More news about: NeuroSense
Sep 10, 2025, 10:00 ET Health Canada Approves Slenyto® - Extended-Release Melatonin Formulation - as a Prescription Drug for Insomnia in Children with Autism Spectrum disorder and Smith Magenis Syndrome
commercially available in 45 countries around the world. Neurim has a strong and innovative product pipeline targeting central nervous system (CNS) disorders. * https://health-products.canada.ca/dpd-bdpp/dispatch-repartition
More news about: Neurim Pharmaceuticals
Sep 10, 2025, 10:00 ET Health Canada Approves Slenyto® - Extended-Release Melatonin Formulation - as a Prescription Drug for Insomnia in Children with Autism Spectrum disorder and Smith Magenis Syndrome
commercially available in 45 countries around the world. Neurim has a strong and innovative product pipeline targeting central nervous system (CNS) disorders. * https://health-products.canada.ca/dpd-bdpp/dispatch-repartition
More news about: Neurim Pharmaceuticals
Sep 10, 2025, 06:00 ET Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), an advanced clinical-stage
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Sep 10, 2025, 04:00 ET Cumulus Neuroscience Appoints Robert Ballantine to Board of Directors
look forward to working with Robert to optimize our commercialization efforts focused on increasing adoption of the NeuLogiq® Platform in CNS clinical studies, with a focus on accelerating much needed therapies for patients and their caregivers living with life altering neurodegenerative and
More news about: Cumulus Neuroscience
Sep 10, 2025, 02:30 ET LUNDBECK SELECTS SWIXX AS A KEY PARTNER IN A TRANSFORMATIVE MULTI-REGIONAL DEAL
"Lundbeck has built a well-established and long-standing presence in the CNS space, and we are proud to carry that legacy forward. To strengthen our ability to support this strategic partnership, we will establish a dedicated CNS Business Unit within the Swixx organization." Dr. Marek
More news about: Swixx BioPharma
Sep 09, 2025, 16:25 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for August 2025
YORK, Sept. 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $90.4 billion as of August 31, 2025,
More news about: Cohen & Steers, Inc.
Sep 09, 2025, 08:32 ET Bee-Sting Inspired Microneedles from Chung-Ang University Could Revolutionize Drug Delivery
Bee Stinger-Like Wearable Electrospun Web Microneedles for Sustained CNS Drug Delivery Journal:
More news about: Chung-Ang University
Sep 09, 2025, 07:00 ET Corero Network Security Advances Software-First Approach with Hardware-Agnostic Support
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today announced support of its
More news about: Corero Network Security
Sep 09, 2025, 03:30 ET CONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for Fragile X Syndrome with EIC Accelerator Support
Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in central nervous system (CNS) disorders, today announced the launch of studies for the pediatric development program of CTH120, an investigational FXS treatment, following positive
More news about: CONNECTA Therapeutics
Sep 08, 2025, 14:30 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
a pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Sep 08, 2025, 11:36 ET Saol Therapeutics Receives Complete Response Letter from FDA for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD)
GA, Dublin, Ireland, and Hamilton, Bermuda. Saol is focused on development activity in CNS disorders such as spasticity and pain management, and orphan diseases. Saol is committed to providing and advancing therapeutic options for patients
More news about: Saol Therapeutics
Sep 08, 2025, 09:46 ET Connected Nation unveils the BEAD Tracker: An interactive tool that tracks federal broadband funding disbursements
service providers — in fact, all Americans — need to see how states plan to invest those funds. We built this dashboard in response to that need." CN's BEAD Tracker (
More news about: Connected Nation
Sep 08, 2025, 01:09 ET नए रोगी अनुभव में सुधार करते हुए, Medidata ने eCOA के लिए Everest Group के PEAK Matrix® आंकलन में अग्रणी स्थान हासिल किया
साझेदारी के साथ, Medidata eCOA को वैज्ञानिक तटस्थता के साथ और अधिक उन्नत किया गया है जिसका उद्देश्य रेटर के बोझ को कम करते हुए सेंट्रल नर्वस सिस्टम (CNS) परीक्षणों में संकेतों का पता लगाने में सुधार करना है। Medidata के रोगी अनुभव के वरिष्ठ उपाध्यक्ष, Matt Noble,
More news about: Medidata
Sep 07, 2025, 04:45 ET Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.